quantisnow
FeedTopReportsPricing
⌘K
Live feed
09:02:00·1d
PRRelease
Alpha Tau Medical Ltd. logo

Alpha Tau Announces FDA Approval of IDE Supplement to Expand Alpha DaRT® IMPACT Trial to Patients with Pancreatic Cancer Receiving Gemcitabine with Abraxane® (Nab-Paclitaxel)

DRTS· Alpha Tau Medical Ltd.
Health Care
Original source

Companies

  • DRTS
    Alpha Tau Medical Ltd.
    Health Care

Recent analyst ratings

  • Mar 4UpdatePiper Sandler$5.00
  • Dec 15UpdateCitigroup$8.00
  • Apr 24UpdateH.C. Wainwright$9.00
  • Apr 14UpdateCantor Fitzgerald$20.00
  • Apr 8UpdatePiper Sandler$19.00
  • Apr 4UpdateCitigroup$21.00

Related

  • SEC1d
    SEC Form 6-K filed by Alpha Tau Medical Ltd.
  • PR1d
    Alpha Tau Successfully Treats First Pancreatic Cancer Patient in Europe with Alpha DaRT® in French Multicenter ACAPELLA Clinical Trial
  • SEC24d
    SEC Form 6-K filed by Alpha Tau Medical Ltd.
  • PR24d
    Alpha Tau Announces First-Ever Oral Presentation of Alpha DaRT® Pancreatic Cancer Data at Digestive Disease Week (DDW) 2026
  • INSIDER36d
    SEC Form 3 filed by new insider Avruch Michael
  • INSIDER36d
    SEC Form 3 filed by new insider Kidron Nadav
  • INSIDER36d
    SEC Form 3 filed by new insider Sofer Uzi
  • INSIDER36d
    SEC Form 3 filed by new insider Adler Alan
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022